Drug reference
imatinib mesylate
Tyrosine Kinase Inhibitor · Antineoplastic agent
Tyrosine Kinase InhibitorAntineoplastic agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
X
FDA category + note
Mechanism
Binds to the BCR::ABL1 ATP-binding domain, inhibiting its kinase activity, preventing the activation of transformation pathways, and inhibiting downstream signaling. Inhibits proliferation of CML cells and induces apoptosis, allowing reemergence of normal hematopoiesis.
Indications
All phases of CML
Dosing
- Adult
- 400 mg daily
Side effects
Common
fluid retentionweight gainnauseadiarrheaskin rashesperiorbital edemabone or muscle achesfatigue
Serious
- renal dysfunction
- renal failure
Pregnancy & lactation
Pregnancy
X
Drug interactions
12 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.
Related guidelines
Other Tyrosine Kinase Inhibitor drugs
Ask House about imatinib mesylate
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Harrison 22e·Updated: 2026-05-10